OTC Markets
Prev Close 0.16
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.10 / 0.19
Exchange OTC Markets
Shares Outstanding 28.83B
Market Cap 4.58M
Div & Yield N.A. (N.A)
Thursday's Health Winners & Losers

Thursday's Health Winners & Losers

AtheroGenics was up and Affymetrix was down in an uneven market for health care stocks.

Market Remains Uneven

It's been a gamble trying to figure out which stocks will catch genuine bids.

Amgen Meets Estimates

But it guides full-year earnings to the low end of expectations. Ratings: Stock Upgrades, Downgrades

Harbin Electric, ImClone, CPI and Bowne & Co. upgraded; RF Industries and General Communication downgraded.

Real Story: Earnings, M&A and Housing Drama

John Bollinger says the market looks good as earnings season starts amid more drama in housing, biotech and M&A.

Looking Up as Earnings Arrive

John Bollinger says the market is strong as Alcoa kicks off earnings season. Plus, drama in housing, biotech and M&A moves stocks.

Study Setback Rocks ImClone

The company's shares fall as an Erbitux trial disappoints.

Feuerstein's Biotech Mailbag

Feuerstein's Biotech Mailbag

Love-hate with Amgen, the ArQule buzz and a Spectrum opportunity.

Wednesday's Health Winners & Losers

A Swiss drug company's acquisition of BioVeris vaulted the company's stock.

Wednesday's Health Winners & Losers

Vertex Pharmaceuticals is up.

Running in Place

It's hard to find patterns here that aren't overextended to the upside.

Another Up Day for Dow

Oil prices climb amid new tensions in the Middle East.

Friday's Health Winners & Losers

Amgen is dropping.

Amgen Setback Boosts ImClone

ImClone shares surge 21% on hope for wider use of Erbitux.

Thursday's Health Winners & Losers

Avalon Pharmaceuticals is down.

ImClone's Next Blockbuster

A pivotal pancreatic cancer study could mean big things for Erbitux.

Feuerstein's Biotech Mailbag

Feuerstein's Biotech Mailbag

This week, Bioenvision, Nuvelo and Neurocrine.

Friday's Health Winners & Losers

Merck is higher.

At Amgen, Focus on Drug Results

Sales potential for Vectibix will be an important tell in its report.

Stockpickr: How to Trade Like Carl Icahn

Stockpickr: How to Trade Like Carl Icahn

He recently added another cancer stock to his portfolio.

Imclone Rises on Erbitux Study

Shares gain 5%.

No Anxiety for Tech, Biotech

The Nasdaq jumps despite worries about the economy, the Fed, commodities and the rally's age.

Tech Tips the Scales

Action in energy and biotech stocks might suggest a slowing economy, but not with a raging tech sector.

Thursday's Health Winners & Losers

Amgen rises on an upgrade.

Cramer's 'Mad Money Lightning Round': Vertex Very Good

Cramer's 'Mad Money Lightning Round': Vertex Very Good

The biotech is making progress with its drug for hepatitis C.

Erbitux Results Mixed in Two Studies

It improves survival in one phase III trial but not in another.

Funny Money: GAAP Is for Sissies

Skilling's sentencing is the end of corporate scandals ... umm, maybe not. Plus, don't cross Jobs.

Maven: Mr. No Cahn Do

The business media fail to note that corporate raider Carl Icahn lacks more than just scientific expertise.

Bristol-Myers Boosts Guidance

Quarterly sales and earnings decline year over year.

A Welcome Rise
in Volume

Energy stocks have come back into favor, and volume in these names has risen.